中国临床药理学杂志2017，Vol.33Issue(21)：2104-2106,3.DOI:10.13699/j.cnki.1001-6821.2017.21.004
乙酰半胱氨酸泡腾片治疗阻塞性睡眠呼吸暂停低通气综合征的临床研究
Clinical trial of acetylcysteine effervescent tablets in the treatment of obstructive sleep apnea hypopnea syndrome
摘要
Abstract
Objective To observe the clinical efficacy and safety of acetylcysteine effervescent tablets in the treatment of obstructive sleep apnea hypopnea syndrome (OSAHS).Methods One hundred patients with OSAHS were divided into control group and treatment group with 50 cases per group.Control group was given the conventional treatment with low flow oxygen absorption,functional exercise and diet.Treatment group was given acetylcysteine effervescent tablet 600 mg,qd,oral,on the basis of control group.Two groups were treated for 12 weeks.The clinical efficacy,serum endothelin-1 (ET-1),nitric oxide (NO),interleukin-6 (IL-6),tumor necrosis factor-α (TNF-α) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 90.00％ (45 cases/50 cases) and 74.00％ (37 cases/50 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:ET-1 were (39.24 ±5.50) and (46.28 ±0.12)ng · L-1,NO were (56.25 ±7.05) and (48.88 ±5.60)μmol · L-1,IL-6 were (41.48 ±4.91) and (65.77 ±9.10)ng · L-1,TNF-α were (28.37 ±3.42) and (42.32 ± 6.21) ng · L-1,the differences were statistically significant (all P ＜ 0.05).There were no adverse drug reactions occurred between two groups.Conclusion Acetylcysteine effervescent tablet has a definitive clinical efficacy and safety in the treatment of OSAHS,which can adjust the levels of ET-1,NO,IL-6 and TNF-α.关键词
乙酰半胱氨酸泡腾片/阻塞性睡眠呼吸暂停低通气综合征/安全性Key words
acetylcysteine effervescent tablet/obstructive sleep apnea hypopnea syndrome/safety分类
医药卫生引用本文复制引用
王灿灿,冯月娟,郁东伟,陈学远..乙酰半胱氨酸泡腾片治疗阻塞性睡眠呼吸暂停低通气综合征的临床研究[J].中国临床药理学杂志,2017,33(21):2104-2106,3.基金项目
杭州市社会发展自主申报基金资助项目(2016533B20) （2016533B20）
